AIM ImmunoTech Inc. (AIM)
| Market Cap | 7.15M-92.7% |
| Revenue (ttm) | n/a-21.5% |
| Net Income | n/a+11.7% |
| EPS | n/a+57.7% |
| Shares Out | 39.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,843 |
| Open | 0.18 |
| Previous Close | 0.18 |
| Day's Range | 0.18 - 0.18 |
| 52-Week Range | 0.17 - 2.79 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | n/a |
AIM ImmunoTech Inc. has a live Insider Score.
Scored on 4 qualifying trades from 1 insider in the last 90 days.
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AIM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AIM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AIM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AIM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AIM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AIM from public contracts
Source: USAspending.gov
AIM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AIM’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score